<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Coronary artery stent thrombosis: Clinical presentation and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Coronary artery stent thrombosis: Clinical presentation and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Coronary artery stent thrombosis: Clinical presentation and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Cutlip, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephan Windecker, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1043308818"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Coronary artery stents, particularly drug-eluting stents, are used in the majority of patients who undergo percutaneous coronary intervention (PCI) to improve symptoms in patients with obstructive coronary artery disease. They function both to prevent abrupt closure of the stented artery soon after the procedure as well as to lower the need for repeat revascularization compared to balloon angioplasty alone (formerly referred to as percutaneous transluminal coronary angioplasty).</p><p>Stent thrombosis is an uncommon but serious complication of PCI with stenting. Most patients present with an acute coronary syndrome, usually with ST-segment elevation on the electrocardiogram. Its cause is total or subtotal thrombotic occlusion of a coronary artery by thrombus that originates in or close to an intracoronary stent. This finding is seen at the time of coronary angiography, which is necessary in most cases to secure the diagnosis. Death and myocardial infarction are not infrequent complications of stent thrombosis.</p><p>This topic will discuss the presentation and management of and outcomes after acute coronary artery stent thrombosis. Issues related to its incidence, timing, risk factors, and prevention are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors"</a> and  <a class="medical medical_review" href="/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients"</a>.)</p><p class="headingAnchor" id="H2912495943"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>Although earlier clinical trials posed a problem for comparing stent thrombosis rates due to non-standardized definition, since 2007, most trials have adopted the criteria and classification proposed by the Academic Research Consortium (ARC) [<a href="#rid1">1</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definite</strong> – Angiographic confirmation of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent, with or without vessel occlusion, which is associated with acute onset of ischemic symptoms at rest or electrocardiographic (ECG) signs of acute ischemia or typical rise and fall in cardiac biomarkers within 48 hours of angiography <strong>or</strong> pathologic confirmation of stent thrombosis determined at autopsy or from tissue obtained following thrombectomy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Probable</strong> – Unexplained death occurring within 30 days after the index procedure, or a myocardial infarction occurring at any time after the index procedure that was documented by ECG or imaging to occur in an area supplied by the stented vessel in the absence of angiographic confirmation of stent thrombosis or other culprit lesion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Possible</strong> – Unexplained death occurring more than 30 days after the index procedure. Of note, the possible category was dropped in an update of the definitions due to lack of specificity with longer-term follow-up.</p><p></p><p>In the discussion that follows, studies using definitions other than ARC will be noted.</p><p class="headingAnchor" id="H1043309813"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Patients with stent thrombosis usually present with an acute coronary syndrome (ACS; unstable angina, non-ST elevation myocardial infarction [NSTEMI], or ST-elevation MI [STEMI]). (See  <a class="medical medical_review" href="/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department"</a>.)</p><p>In most cases, patients present with criteria for the diagnosis of acute STEMI [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction"</a>.) In a report from the United States CathPCI Registry, among almost 7100 cases of stent thrombosis identified during a 16-month period, approximately 60 percent presented with STEMI, 23 percent with NSTEMI, and 17 percent with unstable angina [<a href="#rid3">3</a>]. Patients with early stent thrombosis (&lt;1 month after stent placement) are somewhat more likely to develop cardiogenic shock than those with late (1 to 12 months) or very late (&gt;12 months) stent thrombosis [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/44.html" rel="external">"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction", section on 'Clinical presentation'</a>.)</p><p>At the time of coronary angiography, most patients have complete thrombotic occlusion (TIMI flow grade 0) of the involved vessel  (<a class="graphic graphic_table graphicRef51941" href="/d/graphic/51941.html" rel="external">table 1</a>) [<a href="#rid3">3</a>]. The culprit lesion is more common in the left anterior descending artery (48 percent) in patients with early and late stent thrombosis, whereas the right coronary artery (38 percent) is more commonly involved in cases of very late stent thrombosis [<a href="#rid3">3</a>].</p><p>In the CathPCI Registry, 1.8 percent of all PCI for ACS were attributable to stent thrombosis [<a href="#rid3">3</a>]. In a 2012 report from two hospitals in Minneapolis, Minnesota, USA, nearly 11 percent of all STEMI was attributable to definite stent thrombosis according to the Academic Research Consortium (ARC) criteria [<a href="#rid4">4</a>]. These data have not been updated, but our experts believe this frequency is likely lower with contemporary DES.</p><p>While the possibility of stent thrombosis should be considered in any patient who presents with ACS after stent placement, particularly within one year, there is no information from the history, physical examination, or electrocardiogram (ECG) that can be used to clearly discriminate between stent thrombosis and ACS due to ischemia from a lesion(s) not related to prior stent placement. In the presence of ST-elevation or other changes suggestive of target (stented) vessel ischemia, the suspicion for stent thrombosis should be higher. Such an event would be classified as probable stent thrombosis by the ARC criteria unless angiography confirms another culprit. (See <a class="local">'Definitions'</a> above.)</p><p class="headingAnchor" id="H4282817272"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The definition of definite stent thrombosis is as follows: angiographic or tissue (from thrombectomy at the time of angiography) confirmation of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent, with or without vessel occlusion, which is associated with acute onset of ischemic symptoms at rest or ECG signs of acute ischemia or typical rise and fall of cardiac biomarkers within 48 hours of angiography. Definite stent thrombosis may also be determined by pathologic confirmation of stent thrombosis at the time of an autopsy. (See  <a class="medical medical_review" href="/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients", section on 'Duration and Type of Antiplatelet Treatment'</a>.) </p><p>While the (incidental) finding of thrombus within a stent in a patient without clinical findings is possible, this is likely infrequent. Most of these individuals will have an ACS or have an elevated troponin value.</p><p class="headingAnchor" id="H1128708641"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Patients with ST-elevation myocardial infarction (STEMI) due to stent thrombosis should be managed with primary percutaneous coronary intervention, although restoration of blood flow with intracoronary fibrinolysis has been used [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/15358.html" rel="external">"Primary percutaneous coronary intervention in acute ST-elevation myocardial infarction: Periprocedural management"</a>.) </p><p>Since stents are often placed in proximal segments of major coronary arteries, acute thrombotic occlusion presents as severe ischemia or MI, often STEMI [<a href="#rid5">5-7</a>]. The approach to the management of patients with unstable angina or acute MI is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/d/html/68.html" rel="external">"Overview of the acute management of non-ST-elevation acute coronary syndromes"</a>.)</p><p>The management of patients with stent thrombosis is similar to that for other patients with an acute coronary syndrome (ACS). However, as outcomes in these patients appear to be worse than in individuals with ACS due to plaque rupture in a native coronary artery, it is critically important that the time to reperfusion be as short as possible. (See <a class="local">'Compared with de novo coronary thrombosis'</a> below.) While a non-urgent invasive or a conservative strategy may be reasonable for some patients with unstable angina or non-ST elevation MI who have not had prior stenting, urgent coronary angiography should be considered for most patients in whom the diagnosis of stent thrombosis has been considered.</p><p class="headingAnchor" id="H1128708648"><span class="h2">Periprocedural considerations</span><span class="headingEndMark"> — </span>Recanalization of the occluded artery is possible in over 95 percent of cases. Manual thrombus aspiration can be used in this setting [<a href="#rid3">3</a>] and, in one study, was associated with greater epicardial and microvascular myocardial perfusion [<a href="#rid8">8</a>]. Similar to patients with STEMI due to de novo thrombosis, we do not perform thrombectomy routinely in cases of stent thrombosis, but given potential for larger thrombus burden, it may have a role in some cases. (See  <a class="medical medical_review" href="/d/html/81.html" rel="external">"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST-elevation myocardial infarction", section on 'Thrombectomy'</a>.)</p><p>In some cases, contributing factors such as suboptimal stent apposition or prior placement of an undersized stent are present. We perform intravascular ultrasound in all cases of stent thrombosis when possible and use this information for subsequent stent sizing and to confirm complete stent apposition. (See  <a class="medical medical_review" href="/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors", section on 'Risk factors'</a>.)</p><p>Some experts feel that new stent implantation should be avoided unless there is a clear indication such as a flow-limiting dissection. However, in many cases, we repeat stent placement unless thrombus aspiration and balloon angioplasty yield an optimal result. As in patients with de novo stenting, we prefer drug-eluting over bare-metal stents in almost all patients. Given the risk for recurrence, compliance with the recommended duration of dual antiplatelet therapy (DAPT) is critical after repeat stenting. (See  <a class="medical medical_review" href="/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients", section on 'Summary and recommendations'</a>.)</p><p>The periprocedural antithrombotic approach, including the use of parenteral antiplatelet and anticoagulant therapies, does not differ from that recommended for patients with acute STEMI. (See  <a class="medical medical_review" href="/d/html/92.html" rel="external">"Acute ST-elevation myocardial infarction: Management of anticoagulation"</a> and  <a class="medical medical_review" href="/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy"</a>.)</p><p class="headingAnchor" id="H1128708655"><span class="h2">Long-term antiplatelet therapy</span><span class="headingEndMark"> — </span>Poor compliance with the recommendation for DAPT is a common cause of stent thrombosis within one year and especially within 30 days. (See  <a class="medical medical_review" href="/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors", section on 'Risk factors'</a>.) </p><p>In addition, resistance to <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> may be an important contributing factor in some cases. The optimal approach to antiplatelet therapy after stent thrombosis in patients who demonstrate clopidogrel nonresponse on platelet testing, or a genetic predisposition to it, is not known. (See  <a class="medical medical_review" href="/d/html/6684.html" rel="external">"Clopidogrel resistance and clopidogrel treatment failure", section on 'Definitions'</a>.)</p><p>In patients who present with stent thrombosis while on <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, it is likely the risk of recurrent stent thrombosis is increased. While no trials of alternate antiplatelet regimens, such as switching to <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> or higher-dose clopidogrel, have been performed in these patients, we believe that the benefit from the use of more potent antiplatelet therapy outweighs the increase in risk of bleeding in most patients. Therefore, we suggest discharging the patient on prasugrel 10 mg daily or ticagrelor 90 mg twice daily, in addition to <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>. The minimum duration of DAPT should be one year, with longer courses for patients who are tolerating such therapy. </p><p>Similarly, for patients who present with stent thrombosis after completing the recommended duration of treatment with <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, the optimal preventative antiplatelet strategy is unknown. We suggest initiating <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> 10 mg daily or <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> 90 mg twice daily after an appropriate loading dose rather than restarting clopidogrel and continuing DAPT for a minimum of one year or longer in patients tolerating this regimen. However, in patients who will not receive either prasugrel or ticagrelor, clopidogrel 75 mg daily after a 600 mg loading dose (in addition to <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>) should be restarted.</p><p>In patients who have sustained stent thrombosis, the optimal duration of DAPT is unknown. While we suggest continuing DAPT for more than one year in all patients with stent thrombosis, continual monitoring of the relative benefits and risks (primarily the risk of bleeding) is necessary. Many operators prefer indefinite DAPT after stent thrombosis unless a remediable factor is identified or higher bleeding risk is a concern.</p><p class="headingAnchor" id="H1043309820"><span class="h1">OUTCOMES</span></p><p class="headingAnchor" id="H1043309828"><span class="h2">MI and death</span><span class="headingEndMark"> — </span>The following studies highlight high rates of myocardial infarction (MI) and death after acute stent thrombosis: </p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with an acute coronary syndrome and angiographically-confirmed (definite) stent thrombosis in a pooled analysis, the 30-day rate of MI was 60 percent [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The 30-day mortality rates after stent thrombosis are 7 percent for angiographically confirmed and 19 percent for clinically identified stent thrombosis for bare metal stents (BMS) based upon pooled clinical trial data [<a href="#rid6">6</a>] and 15 percent with drug-eluting stents (DES) based upon a large real-world registry [<a href="#rid9">9</a>]. One study of 7315 stent thrombotic events found that in-hospital mortality was higher in patients with early stent thrombosis (up to 30 days after stent placement) compared with late (30 days to one year) and very late stent (after one year) thrombosis (7.9 versus 3.8 and 3.6 percent; p &lt;0.01) [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Six-month mortality is between 20 and 25 percent among survivors of stent thrombosis [<a href="#rid10">10</a>]. Some studies have reported higher six-month mortality rates after stent thrombosis with DES compared to BMS (17 to 45 percent [<a href="#rid11">11-14</a>] and 9 to 21 percent [<a href="#rid5">5,6</a>], respectively). However, other studies have shown equivalent mortality [<a href="#rid14">14</a>]. Predictors of six-month mortality include very late stent thrombosis, implantation of a stent during percutaneous coronary intervention (PCI) for stent thrombosis, and failure to achieve optimal angiographic reperfusion [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mortality at one year after definite DES thrombosis is between 10 and 20 percent [<a href="#rid10">10,15-17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Longer-term mortality (450 days) after definite stent thrombosis was 22 percent in the TRITON-TIMI 38 trial of acute coronary syndrome patients who were randomly assigned to either <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> or <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> and then underwent PCI with stenting [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The overall rates of death and MI at four years were 31 and 83 percent, respectively, after definite or possible stent thrombosis (Academic Research Consortium definition) in a pooled analysis of eight randomized trials comparing DES to BMS [<a href="#rid19">19</a>]. The outcomes with DES and BMS stent thrombosis were combined.</p><p></p><p class="headingAnchor" id="H1043309835"><span class="h2">Recurrent stent thrombosis</span><span class="headingEndMark"> — </span>Although not well studied, the incidence of recurrent stent thrombosis is relatively high. In a review of 95 patients with BMS thrombosis, 11 patients (12 percent) had recurrent stent thrombosis at six months [<a href="#rid5">5</a>]. In a registry of DES, recurrence was 4.6 percent at one year [<a href="#rid15">15</a>]. In a report of 431 patients in the Dutch stent thrombosis registry, the cumulative incidence of definite or probable recurrent stent thrombosis was 20.1 percent at three years [<a href="#rid16">16</a>].</p><p>Angiographic predictors of recurrent stent thrombosis include a larger post-procedural vessel diameter and a larger residual thrombus burden [<a href="#rid20">20</a>]. </p><p class="headingAnchor" id="H1043309842"><span class="h2">Compared with de novo coronary thrombosis</span><span class="headingEndMark"> — </span>ST-elevation MI (STEMI) is characterized by intraluminal thrombus irrespective of whether the initial event is de novo (in association with plaque rupture) or stent related. However, clinical outcomes appear worse with the latter [<a href="#rid6">6,10</a>]. (See  <a class="medical medical_review" href="/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients", section on 'Duration and Type of Antiplatelet Treatment'</a>.)</p><p>In an attempt to understand this difference, clinical and angiographic outcomes in patients with STEMI due to stent thrombosis (n = 92) and de novo coronary thrombosis (n = 98) were compared in a retrospective study of patients who underwent primary PCI for STEMI [<a href="#rid10">10</a>]. The following findings were noted in patients with stent thrombosis compared to those with de novo coronary thrombosis:</p><p class="bulletIndent1"><span class="glyph">●</span>In-hospital major adverse cardiovascular and cerebrovascular events were significantly higher (22.6 versus 9.2 percent), including a significantly higher in-hospital death rate (17.4 versus 7.1 percent). However, there were no differences at six-month follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Successful reperfusion using angiographic criteria was significantly lower (80.4 versus 96.9 percent)</p><p></p><p>In another study of approximately 3300 patients with STEMI between 2002 and 2010, mortality was similar between those with STEMI due to stent thrombosis compared to those with de novo coronary thrombosis [<a href="#rid4">4</a>]. However, the rate of reinfarction was higher in those with stent thrombosis.</p><p>In a cohort of 2464 individuals with STEMI treated with primary PCI, the mid-term outcomes of those with angiographically proven stent thrombosis (3 percent) were compared to those with a primary coronary artery event (97 percent) [<a href="#rid21">21</a>]. At six months, those with stent thrombosis were shown to have significantly higher rates of non-fatal MI and restenosis/reocclusion (54 versus 17 and 10 versus 1 percent), while the rate of death was not significantly different (12 versus 8 percent).</p><p class="headingAnchor" id="H176751956"><span class="h1">INTRAPROCEDURAL STENT THROMBOSIS</span><span class="headingEndMark"> — </span>The importance of intraprocedural stent thrombosis (IPST) as a risk factor for subsequent mortality and recurrent thrombosis has been highlighted [<a href="#rid22">22,23</a>]. IPST was defined as the development of occlusive or non-occlusive new or increasing thrombus in or adjacent to a recently implanted stent before the percutaneous coronary intervention (PCI) procedure is completed. IPST is not included in the Academic Research Consortium (ARC) definitions and thus its presentation and management are not evaluated uniformly in studies of stent thrombosis [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors", section on 'Definitions'</a> and  <a class="medical medical_review" href="/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors", section on 'Intraprocedural stent thrombosis'</a>.)</p><p>In a study of over 10,000 individuals who underwent PCI with stenting, patients with IPST had a higher rate of composite ischemia (death, MI, ischemia-driven revascularization, or new-onset out-of-laboratory stent thrombosis) at 48 hours and 30 days compared to those without IPST (29.2 versus 4.5 and 31.5 versus 5.7 percent, respectively) [<a href="#rid23">23</a>]. The finding of a significantly higher rate of ARC definite or probable stent thrombosis at 30 days has been noted in other studies [<a href="#rid22">22</a>]. Most cases were in the setting of non-ST elevation acute coronary syndrome or ST elevation myocardial infarction. The impact of thrombus burden and the no-reflow phenomenon may be important contributors. While clearly distinguished from classic stent thrombosis after a successful procedure, the known adverse consequences of procedural complications remain important and ongoing studies are needed to assess methods for improved procedural success in these high-risk patients.</p><p class="headingAnchor" id="H1332717981"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119297.html" rel="external">"Society guideline links: Percutaneous coronary intervention"</a>.)</p><p class="headingAnchor" id="H1043308826"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background and clinical presentation </strong>– Stent thrombosis is an uncommon but serious complication of percutaneous coronary intervention with stenting from a total or subtotal thrombotic occlusion of a coronary artery by thrombus that originates in or close to an intracoronary stent. Most patients with stent thrombosis present with an acute coronary syndrome (ACS), usually with ST-segment elevation on the electrocardiogram. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– Stent thrombosis is seen at the time of coronary angiography; this test is necessary in most cases to secure the diagnosis. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Procedural </strong>– In general, the acute management of patients with stent thrombosis is similar to that for other patients with an ACS. Important points include considering the diagnosis in any patient ACS with prior stent placement and a rapid attempt to restore vessel patency. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antiplatelet therapy </strong>– For patients diagnosed with stent thrombosis while on <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, we suggest switching the patient to <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> 10 mg daily or <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> 90 mg twice daily (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Long-term antiplatelet therapy'</a> above.)</p><p></p><p class="bulletIndent2">For patients diagnosed with stent thrombosis who have completed the minimum recommended course of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, we suggest starting <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> 10 mg daily or <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> 90 mg twice daily (after appropriate loading doses), rather than restarting clopidogrel 75 mg daily given the ACS setting (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Long-term antiplatelet therapy'</a> above.) </p><p></p><p class="bulletIndent2">In patients with stent thrombosis, irrespective of whether they were or were not on dual antiplatelet therapy (DAPT) at the time of the event, we suggest DAPT for a minimum of one year after the event, rather than shorter periods of time (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The ultimate duration of DAPT will require continual assessment of the benefits and risks (in particular, bleeding risk). </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115:2344.</a></li><li><a class="nounderline abstract_t">Holmes DR Jr, Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol 2010; 56:1357.</a></li><li><a class="nounderline abstract_t">Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. JACC Cardiovasc Interv 2012; 5:131.</a></li><li><a class="nounderline abstract_t">Brodie BR, Hansen C, Garberich RF, et al. ST-segment elevation myocardial infarction resulting from stent thrombosis: an enlarging subgroup of high-risk patients. J Am Coll Cardiol 2012; 60:1989.</a></li><li><a class="nounderline abstract_t">Wenaweser P, Rey C, Eberli FR, et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 2005; 26:1180.</a></li><li><a class="nounderline abstract_t">Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103:1967.</a></li><li><a class="nounderline abstract_t">Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496.</a></li><li><a class="nounderline abstract_t">Mahmoud KD, Vlaar PJ, van den Heuvel AF, et al. Usefulness of thrombus aspiration for the treatment of coronary stent thrombosis. Am J Cardiol 2011; 108:1721.</a></li><li><a class="nounderline abstract_t">Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45:947.</a></li><li><a class="nounderline abstract_t">Chechi T, Vecchio S, Vittori G, et al. ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients. J Am Coll Cardiol 2008; 51:2396.</a></li><li><a class="nounderline abstract_t">Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126.</a></li><li><a class="nounderline abstract_t">Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45:2088.</a></li><li><a class="nounderline abstract_t">Mishkel GJ, Moore AL, Markwell S, et al. Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents. J Am Coll Cardiol 2007; 49:181.</a></li><li><a class="nounderline abstract_t">Burzotta F, Parma A, Pristipino C, et al. Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study. Eur Heart J 2008; 29:3011.</a></li><li><a class="nounderline abstract_t">de la Torre-Hernández JM, Alfonso F, Hernández F, et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 2008; 51:986.</a></li><li><a class="nounderline abstract_t">van Werkum JW, Heestermans AA, de Korte FI, et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation 2009; 119:828.</a></li><li><a class="nounderline abstract_t">Kimura T, Morimoto T, Kozuma K, et al. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation 2010; 122:52.</a></li><li><a class="nounderline abstract_t">Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008; 371:1353.</a></li><li><a class="nounderline abstract_t">Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356:1020.</a></li><li><a class="nounderline abstract_t">Porto I, Burzotta F, Parma A, et al. Angiographic predictors of recurrent stent thrombosis (from the Outcome of PCI for stent-ThrombosIs MultIcentre STudy [OPTIMIST]). Am J Cardiol 2010; 105:1710.</a></li><li><a class="nounderline abstract_t">Parodi G, Memisha G, Bellandi B, et al. Effectiveness of primary percutaneous coronary interventions for stent thrombosis. Am J Cardiol 2009; 103:913.</a></li><li><a class="nounderline abstract_t">Brener SJ, Cristea E, Kirtane AJ, et al. Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndromes. JACC Cardiovasc Interv 2013; 6:36.</a></li><li><a class="nounderline abstract_t">Généreux P, Stone GW, Harrington RA, et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol 2014; 63:619.</a></li></ol></div><div id="topicVersionRevision">Topic 87310 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470709" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical end points in coronary stent trials: a case for standardized definitions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20946992" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Stent thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22361596" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23062533" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : ST-segment elevation myocardial infarction resulting from stent thrombosis: an enlarging subgroup of high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728650" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11306525" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8041414" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21906707" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Usefulness of thrombus aspiration for the treatment of coronary stent thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15766834" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18565395" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870416" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15963413" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Late angiographic stent thrombosis (LAST) events with drug-eluting stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222728" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18987096" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18325436" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19188507" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20566955" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18377975" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296821" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Stent thrombosis in randomized clinical trials of drug-eluting stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20538119" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Angiographic predictors of recurrent stent thrombosis (from the Outcome of PCI for stent-ThrombosIs MultIcentre STudy [OPTIMIST]).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19327415" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effectiveness of primary percutaneous coronary interventions for stent thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23266233" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24184169" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
